DV
Dividend Vision

CAMP — CAMP4 THERAPEUTICS CORPORATION

CAMP4 THERAPEUTICS CORPORATION (CAMP)

Total return is -49.3% over the past 1.8 years, 86.0 points behind SPY at 36.7%. Its deepest 1-year drawdown was 57.8%.

Camp4 Therapeutics Corporation is a clinical-stage biopharmaceutical company developing RNA-based therapeutics for genetic diseases, with its lead candidate CMP-001 in Phase 1/2 trials for urea cycle disorders and CMP-002 in development for SYNGAP1-related disorders. The company does not currently distribute dividends. Camp4 Therapeutics appeals to investors seeking exposure to early-stage biotech development rather than income generation.

CAMP key facts

Asset type
Stock
Asset class
Equity
Inception date
10/11/2024
Last close
$5.44
Market cap
$192,644,720
Average volume
426629.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.35